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Although Caenorhabditis elegans has been utilized
extensively to study synapse formation and function,
relatively little is known about synaptic plasticity in
C. elegans. We show that a brief treatment with the
cholinesterase inhibitor aldicarb induces a form of
presynaptic potentiation whereby ACh release at
neuromuscular junctions (NMJs) is doubled. Aldi-
carb-induced potentiation was eliminated by muta-
tions that block processing of proneuropeptides,
by mutations inactivating a single proneuropeptide
(NLP-12), and by those inactivating an NLP-12
receptor (CKR-2). NLP-12 expression is limited to a
single stretch-activated neuron, DVA. Analysis of
a YFP-tagged NLP-12 suggests that aldicarb stimu-
lates DVA secretion of NLP-12. Mutations disrupting
the DVA mechanoreceptor (TRP-4) decreased aldi-
carb-induced NLP-12 secretion and blocked aldi-
carb-induced synaptic potentiation. Mutants lacking
NLP-12 or CKR-2 have decreased locomotion rates.
Collectively, these results suggest that NLP-12medi-
ates a mechanosensory feedback loop that couples
muscle contraction to changes in presynaptic re-
lease, thereby providing a mechanism for proprio-
ceptive control of locomotion.
INTRODUCTION
Neuropeptides represent a vast and chemically diverse set of
neurotransmitters. Proneuropeptides are packaged into large
dense core vesicle (DCV) precursors, where they are processed
into active forms by copackaged enzymes. Many, and perhaps
all, neurons express and secrete neuropeptides. Expression of
specific neuropeptides is often utilized as amarker to distinguish
subclasses of neurons. For example, subclasses of mouse
cortical interneurons are distinguished by their expression of
cholecystokinin and somatostatin (Kawaguchi and Kondo,
2002). Despite their widespread expression, relatively little is92 Neuron 71, 92–102, July 14, 2011 ª2011 Elsevier Inc.known about how specific neuropeptides function within
circuits.
Secretion of neuromodulatory peptides has often been
proposed as a mechanism for regulating synaptic efficacy and
producing adaptive changes in behavior; however, genetic
studies of neuropeptide function have primarily focused on
endocrine functions. In a few cases, the impact of specific neuro-
peptides has been explored in particular circuits. For example,
specific neuropeptides have been implicated in adaptation of
odorant responses (Chalasani et al., 2010; Ignell et al., 2009),
in ethanol sensitivity (Davies et al., 2004; Moore et al., 1998),
and in regulation of circadian behaviors (Lear et al., 2005; Mert-
ens et al., 2005; Renn et al., 1999). Much remains to be learned
about how neuropeptides shape the function of these and other
behavioral circuits.
The nematodeC. elegans has been utilized as a genetic model
to study neuropeptide function. The genome sequence predicts
115 proneuropeptide genes, encoding 250 different mature
peptides (Li and Kim, 2008). Many of these predicted peptides
have been confirmed by mass spectrometry (Husson et al.,
2006, 2007; Husson and Schoofs, 2007). Mutations have been
described that disrupt proneuropeptide processing (egl-3 PC2,
egl-21 CPE, and sbt-1 7B2), maturation of DCVs (unc-108
Rab2 and ric-19 ICA69), and exocytosis of DCVs (unc-31
CAPS and pkc-1 PKC3) (Edwards et al., 2009; Husson and
Schoofs, 2007; Jacob and Kaplan, 2003; Kass et al., 2001;
Sieburth et al., 2005, 2007; Speese et al., 2007; Sumakovic
et al., 2009). Hereafter, we refer to these mutants collectively
as neuropeptide-deficient mutants.
Several prior studies suggested that neuropeptides regulate
transmission at cholinergic NMJs in C. elegans. Sensitivity of
C. elegans to paralysis induced by the cholinesterase inhibitor al-
dicarb has been used as a measure of acetylcholine release
(ACh) at neuromuscular junctions (Miller et al., 1996). Mutations
that decrease ACh secretion confer resistance to aldicarb-
induced paralysis (Nonet et al., 1998; Saifee et al., 1998), while
those that increase ACh secretion cause aldicarb hypersensi-
tivity (Gracheva et al., 2006; McEwen et al., 2006; Vashlishan
et al., 2008). Many neuropeptide-deficient mutants are aldicarb
resistant, implying that endogenous neuropeptides regulate
synaptic transmission (Edwards et al., 2009; Husson and
Schoofs, 2007; Jacob and Kaplan, 2003; Kass et al., 2001;
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Figure 1. Electrophysiological Characterization of egl-3 Mutants
Endogenous EPSCs (A–C), stimulus-evoked EPSCs (D–F), and ACh-evoked currents (G and H) were recorded from body wall muscle of adult worms of the
indicated genotypes, with (blue) and without (black) a 60 min aldicarb treatment. Representative traces of endogenous EPSCs (A), averaged traces of stimulus-
evoked responses (D) and ACh-evoked responses (G), and summary data for all three are shown (B, C, E, F, and H). (I) Aldicarb-induced paralysis is compared for
the indicated genotypes. The number of animals analyzed (B, E, and H) or the number of replicate experiments (I) is indicated for each genotype. Values that are
significantly different from untreated wild-type controls are indicated (***p < 0.001; **p < 0.01). Error bars indicate SEM. A common set of wild recordings (+ and –
aldicarb) were utilized in Figures 1, 2, 3, and 5. All comparisons to this control data set were corrected for multiple comparisons using the Tukey-Kramer test. All
electrophysiological data are shown in Table S1.
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A Neuropeptide Mechanosensory Feedback LoopSieburth et al., 2005, 2007; Speese et al., 2007; Sumakovic et al.,
2009); however, the synaptic basis for the aldicarb resistance of
neuropeptide mutants has not been determined. Electrophysio-
logical recordings have been reported for four neuropeptide-
deficient mutants. In three cases (pkc-1 PKC3, unc-108 Rab2,
and ric-19 ICA69 mutants), baseline transmission was unaltered
whereas in the fourth case (unc-31 CAPS) transmission was
modestly reduced (Edwards et al., 2009; Gracheva et al., 2007;
Sieburth et al., 2007; Sumakovic et al., 2009). This discrepancy
may reflect the fact that CAPS has also been proposed to
directly promote SV exocytosis (Jockusch et al., 2007). Thus, it
remains unclear how neuropeptides alter neuromuscular
signaling.
Here we show that aldicarb treatment potentiates ACh release
in wild-type animals, that the neuropeptide NLP-12 is required
for this effect, and that NLP-12 is secreted by a stretch-activated
mechanosensory neuron (DVA). Collectively, our results suggest
that NLP-12 provides proprioceptive feedback that couplesmuscle contraction to changes in presynaptic release. These
results provide a synaptic mechanism for proprioceptive control
of locomotion behavior.
RESULTS
Mutants Lacking egl-3 PC2 Have Wild-Type Baseline
Synaptic Transmission
To further address the impact of endogenous neuropeptides on
cholinergic transmission, we recorded excitatory postsynaptic
currents (EPSCs) from adult body muscles of egl-3 PC2 mutants
(Figure 1). The egl-3 gene encodes a protease that ismost similar
to proprotein convertase type 2 (PC2) (Kass et al., 2001) and
egl-3 PC2 mutants have severe defects in proneuropeptide pro-
cessing (Husson et al., 2006; Jacob and Kaplan, 2003). Like
other neuropeptide-deficient mutants, egl-3mutants were resis-
tant to aldicarb-induced paralysis (Figure 1I) (Jacob and Kaplan,
2003). We recorded both endogenous EPSCs, which areNeuron 71, 92–102, July 14, 2011 ª2011 Elsevier Inc. 93
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A Neuropeptide Mechanosensory Feedback Loopsynaptic events mediated by the endogenous activity of cholin-
ergic motor neurons, as well as EPSCs evoked by a depolarizing
stimulus. In egl-3 null mutants, the rate, amplitude, and kinetics
of endogenous EPSCs, and the amplitude and total synaptic
charge of evoked EPSCs were all unaltered compared to wild-
type controls (Figure 1; see Figure S1 and Table S1 available on-
line). These results are consistent with prior studies of several
other neuropeptide-defective mutants (e.g., pkc-1 PKC3,
unc-108 Rab2, and ric-19 ICA69) (Edwards et al., 2009; Sieburth
et al., 2007; Sumakovic et al., 2009). Aldicarb resistance can also
arise from increased transmission at GABAergic NMJs (Mullen
et al., 2006), which could potentially explain the phenotype of
neuropeptide mutants. To test this possibility, we recorded
inhibitory postsynaptic currents (IPSCs) from adult body
muscles. The rate and amplitude of endogenous IPSCs ob-
served in egl-3 PC2 mutants were indistinguishable from those
observed in wild-type controls (Figures S1A–S1C). Collectively,
these results suggest that changes in baseline transmission at
cholinergic or GABAergic NMJs cannot account for the aldicarb
resistance of neuropeptide mutants.
Aldicarb Treatment Potentiates Cholinergic
Transmission
Aldicarb sensitivity is assayed by measuring the onset of paral-
ysis during a 2 hr aldicarb treatment. Given the prolonged time
course of these assays, we reasoned that aldicarb exposure
might alter synaptic transmission, which could account for the
discrepancy between the behavioral and electrophysiological
phenotypes of the neuropeptide mutants. To test this idea, we
recorded body muscle EPSCs after a 60 min pretreatment with
aldicarb. Aldicarb treatment significantly increased the rate of
endogenous EPSCs, and the total synaptic charge of evoked
EPSCs, both indicating enhanced cholinergic transmission
(Figures 1A–1F; Table S1). By contrast, aldicarb treatment did
not alter the IPSC rate of either wild-type or egl-3 mutants, sug-
gesting that this effect was specific for cholinergic transmission
(Figures S1A and S1B).
The synaptic potentiation following aldicarb treatment could
be causedbyeither apre- or postsynaptic change. The increased
rate of endogenous EPSCs suggests a presynaptic origin for the
potentiation. Nonetheless, we did several additional experiments
to rule out postsynaptic changes. First, aldicarb treatment did not
alter the amplitude or kinetics of endogenous EPSCs (Figure 1C;
Figures S1D–S1G, and Table S1), both suggesting that muscle
sensitivity to synaptically released ACh was unaltered. Second,
aldicarb treatment did not increase the amplitude of currents
activated by application of exogenous ACh (Figures 1G and 1H;
Table S1). In fact, ACh-activated currents were significantly
decreased by aldicarb treatment. Third, aldicarb treatment did
not increase the abundance of GFP-tagged ACR-16 nicotinic
receptors in body muscles (K.B., unpublished data). Therefore,
aldicarb-induced synaptic potentiation was more likely caused
by a presynaptic change in ACh release.
NLP-12 Is Required for Aldicarb-Induced Synaptic
Potentiation
The resistance of neuropeptide-deficient mutants to aldicarb-
induced paralysis could be caused by defects in aldicarb-94 Neuron 71, 92–102, July 14, 2011 ª2011 Elsevier Inc.induced synaptic potentiation. Consistent with this idea, the
aldicarb-induced increase in EPSC rate and in evoked synaptic
charge were both eliminated in egl-3 PC2 mutants (Figures 1B
and 1F; Table S1). This lack of aldicarb-induced potentiation
was not caused by a generalized defect in synaptic transmission
because endogenous and evoked EPSCs observed in untreated
egl-3 PC2 mutants were indistinguishable from wild-type
controls (Figure 1; Figure S1 and Table S1).
In a large RNAi screen, we found that inactivation of several
proneuropeptide encoding genes (including ins-22, ins-31,
flp-1, and nlp-12) causes resistance to aldicarb-induced paral-
ysis (Sieburth et al., 2005). Aldicarb resistance phenotypes
were confirmed for flp-1 and nlp-12 using available knockout
alleles (Sieburth et al., 2005). The aldicarb resistance of nlp-12
mutants was much stronger than that of flp-1 mutants; conse-
quently, we focused our subsequent analysis on nlp-12.
If an nlp-12-encoded neuropeptide mediates aldicarb-
induced paralysis and synaptic potentiation, then nlp-12 and
egl-3 mutations should have very similar effects on behavior
and synaptic transmission. Several results support this idea.
First, nlp-12 and egl-3 mutations did not have additive effects
on aldicarb-induced paralysis, consistent with their functioning
together in this process (Figure 2C). Second, baseline endoge-
nous and evoked EPSCswere unaltered in nlp-12 single mutants
(Figure 2; Figure S2 and Table S2), as was the case in egl-3 PC2
mutants (Figure 1; Figure S1 and Table S1). Third, the aldicarb-
induced increases in EPSC rate and evoked synaptic charge
were both eliminated in nlp-12 mutants and were restored by
a transgene containing an nlp-12 genomic clone (Figure 2).
Collectively, these results support the idea that an nlp-12-
encoded peptide is required for the behavioral and synaptic
effects of aldicarb.
An NLP-12 Receptor, CKR-2, Is Also Required for
Aldicarb-Induced Potentiation
The ckr-2 gene encodes a G protein-coupled receptor that is
most similar to mammalian gastrin receptors (Janssen et al.,
2008). NLP-12 peptides are high affinity agonists for CKR-2
receptors expressed in tissue culture cells (Janssen et al.,
2008). Prompted by these results, we tested ckr-2 mutants for
defects in aldicarb-induced paralysis and synaptic potentiation.
Like nlp-12 mutants, ckr-2 mutants were resistant to aldicarb-
induced paralysis, had normal baseline cholinergic transmission,
but lacked aldicarb-induced increases in EPSC rate and evoked
synaptic charge (Figure 3; Figure S3 and Table S3). The nlp-12
and ckr-2 mutations did not have additive effects on aldicarb-
induced paralysis nor on baseline synaptic transmission (Fig-
ure 3C; Table S3). A transcriptional reporter containing the
ckr-2 promoter was expressed in both cholinergic and
GABAergic motor neurons (Figure 3F). The behavioral and elec-
trophysiological defects of ckr-2mutants were rescued by trans-
genes expressing CKR-2 in all cholinergic neurons (using the
unc-17 VAChT promoter), in cholinergic motor neurons (using
the acr-2 promoter), but not by those expressed in GABAergic
neurons (using the unc-25 GAD promoter) (Figure 3; Table S3).
These results suggest that CKR-2 functions in cholinergic
neurons, mediating the effects of aldicarb on behavior and
synaptic transmission.
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Figure 2. The Neuropeptide NLP-12 Is Required for Aldicarb-Induced Potentiation of Cholinergic Transmission
Endogenous EPSCs (A and B) and stimulus-evoked EPSCs (D and E) were recorded from body wall muscle of adult worms of the indicated genotypes, with (blue)
and without (black) a 60 min aldicarb treatment. Representative traces of endogenous EPSCs (A), averaged stimulus-evoked responses (D), and summary data
(B and E) are shown. (C) Aldicarb-induced paralysis is compared for the indicated genotypes. Rescue refers to nlp-12 mutants carrying a transgene containing
a 2.1 kb genomic nlp-12 clone in which YFP was fused at the NLP-12 carboxy terminus. DA Rescue refers to nlp-12 mutants carrying a transgene expressing
NLP-12 in DA motor neurons (using the unc-129 promoter). The number of animals analyzed (B and E) or the number of replicate experiments (C) is indicated for
each genotype. Values that are significantly different from untreated wild-type controls are indicated (***p < 0.001). Error bars indicate SEM. A common set of wild
recordings (+ and – aldicarb) were utilized in Figures 1, 2, 3, and 5. All comparisons to this control data set were corrected for multiple comparisons using the
Tukey-Kramer test. All electrophysiological data are shown in Table S2.
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NLP-12’s effects on cholinergic transmission are presynaptic.
In contrast, a prior study showed that NLP-12 application
induces contraction of isolated A. suum muscle strips (McVeigh
et al., 2006), suggesting a direct effect on muscle. Based on
these results, we did several additional experiments to deter-
mine if NLP-12 and CKR-2 have postsynaptic effects. First, we
analyzed ACh-activated muscle currents, finding that the
currents recorded from untreated nlp-12 and ckr-2 mutants
were indistinguishable from wild-type controls (Figures S2D,
S2E, S3D, and S2E and Tables S2 and S3). Second, aldicarb
treatment significantly reduced the amplitude of ACh-activated
currents in wild-type muscles (Figures 1G and 1H; Table S1),
and identical effects were observed in aldicarb-treated nlp-12
(Figures S2D and S2E and Table S2) and ckr-2 (Figures S3D
and S3E and Table S3) mutant muscles. Third, to assess muscle
responses to synaptically released ACh, we analyzed endoge-
nous EPSCs. We found that neither the amplitude nor the
kinetics of endogenous EPSCs were significantly altered in
control and aldicarb treated wild-type (Figures S1D–S1G and
Table S1), nlp-12 (Figures S2A–S2C and Table S2), and ckr-2
(Figures S3A–S3C and Table S3) animals. Thus, changes in
muscle responsiveness to ACh were not observed in nlp-12
and ckr-2 mutants. Finally, the ckr-2 transcriptional reporter
was not expressed in body muscles (data not shown). Collec-
tively, our results are most consistent with the idea thatNLP-12 and CKR-2 potentiate cholinergic transmission through
a presynaptic mechanism.
NLP-12 Is Expressed in DVA Neurons
Weanalyzed a reporter construct containing the nlp-12 promoter
driving expression of GFP. This reporter construct was ex-
pressed in a single tail neuron, DVA, consistent with prior studies
(Janssen et al., 2008).
Fluorescently tagged proneuropeptides have been used to
monitor secretion in C. elegans (Ch’ng et al., 2008; Sieburth
et al., 2007); therefore, we reasoned that a similar approach
could be utilized to analyze NLP-12 secretion. Expression of
NLP-12::YFP in DVA (using the nlp-12 promoter) showed a punc-
tate distribution in the DVA axon, in both the ventral nerve cord
and in the nerve ring (Figure 4A). Several results suggest that
the NLP-12 puncta correspond to DCVs containing NLP-
12::YFP. First, expression of the NLP-12::YFP transgene
rescued the nlp-12mutant defects in aldicarb-induced paralysis
(Figure 2C) and synaptic potentiation (data not shown), demon-
strating that the tagged proneuropeptide retains biological
activity. Second, NLP-12 puncta fluorescence was significantly
increased in unc-13 Munc13 mutants (which are defective for
DCV secretion) (Sieburth et al., 2007; Speese et al., 2007)
(Figures 4A and 4B; Figures S4C and S4D). Taken together,
these results indicate that DVA neurons express and actively
secrete NLP-12.Neuron 71, 92–102, July 14, 2011 ª2011 Elsevier Inc. 95
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Figure 3. The NLP-12 Receptor CKR-2 Is Also Required for Suppression of Aldicarb-Induced Potentiation
(A, B, D, and E) Endogenous EPSCs (A and B) and stimulus-evoked EPSCs (D and E) were recorded from body wall muscle of adult worms of the indicated
genotypes, with (blue) and without (black) aldicarb pretreatment (30 min for ACh rescue, 60 min for all others). Representative traces of endogenous EPSCs (A),
averaged stimulus-evoked responses (D), and summary data (B and E) are shown. ckr-2 mutants containing transgenes driving CKR-2 expression in all
cholinergic neurons (using the unc-17 promoter) [rescue (ACh)], in GABA neurons (using the unc-25 promoter) [rescue (GABA)], and in cholinergic motor neurons
(using the acr-2 promoter) [rescue Pacr-2] are indicated.
(C) Aldicarb-induced paralysis is compared for the indicated genotypes. The number of animals analyzed (B and E) or the number of replicate experiments (C) is
indicated for each genotype.
(F) Pckr-2::NLS::GFP expresses in both cholinergic neurons (Punc-17::mCherry), in GABA neurons (Punc-25::mCherry). Arrows indicated cells bodies. Values
that are significantly different from untreated wild-type controls are indicated (***p < 0.001;*p < 0.05). Error bars indicate SEM. A common set of wild recordings
(+ and – aldicarb) were utilized in Figures 1, 2, 3, and 5. All comparisons to this control data set were corrected for multiple comparisons using the Tukey-Kramer
test. All electrophysiological data are shown in Table S3.
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constructs that we previously analyzed. For other neuropeptides
(e.g., NLP-21::YFP expressed in DA motor neurons), YFP
secreted by neurons is taken up by specialized phagocytic cells
in the body cavity (termed coelomocytes), where it can be quan-
tified as a fluorescent signal (Sieburth et al., 2007). For NLP-
12::YFP, we were unable to detect coelomocyte fluorescence
(Figure S4F). This distinction apparently results from expression
of NLP-12 in the DVA neuron, which has an axon in the ventral
nerve cord. When NLP-12::YFP was expressed in DA neurons,
we observed fluorescent puncta in both dorsal cord axons and
in coelomocytes (Figure S4E); however, this transgene was
unable to rescue the nlp-12 mutant defect in aldicarb-induced
paralysis (Figure 2C). Conversely, when NLP-21::YFP was ex-
pressed in DVA, coelomocyte fluorescence was not detected
(data not shown). These results suggest that YFP secreted in
the ventral nerve cord cannot be internalized by coelomocytes,
perhaps because it is endocytosed by another cell type (e.g.,
the ventral hypodermis, or body muscles) or cannot efficiently
diffuse out of the ventral cord tissue.96 Neuron 71, 92–102, July 14, 2011 ª2011 Elsevier Inc.Aldicarb Treatment Stimulates NLP-12 Secretion from
DVA Neurons
If NLP-12 mediates the effects of aldicarb on behavior and
synaptic transmission, we would expect that aldicarb treatment
would stimulate NLP-12 secretion from DVA. Consistent with
this idea, we found that aldicarb treatment resulted in a rapid
and significant decrease in NLP-12 puncta fluorescence in
DVA axons (Figures 4A and 4B; Figure S4A). This effect was
specific for NLP-12 secretion by DVA, as aldicarb treatment
did not decrease NLP-21 puncta fluorescence in DA motor
neurons (Figures 4C and 4D). The effect of aldicarb on NLP-12
puncta fluorescence was eliminated in both unc-31 CAPS and
unc-13 Munc13 mutants (Figure 4B; Figures S4C and S4D),
implying that the aldicarb-induced decrease in NLP-12 puncta
fluorescence was mediated by increased NLP-12 secretion.
These results support the idea that aldicarb stimulates NLP-12
secretion by DVA neurons, thereby potentiating cholinergic
transmission and paralysis. Consistent with this idea, a trans-
gene driving NLP-12 expression in DA motor neurons failed to
rescue the nlp-12 mutant aldicarb-induced paralysis defect
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Figure 4. Aldicarb Stimulates NLP-12 Secretion
from DVA Neurons
(A and B) Representative images (A) and summary data (B)
for NLP-12::YFP fluorescence in the DVA ventral cord axon
are shown for the indicated genotypes, with and without
aldicarb treatment.
(C and D) Representative images (C) and summary data (D)
for NLP-21::YFP fluorescence in the dorsal cord axons of
wild-type DA motor neurons, with and without aldicarb
treatment are shown. The number of animals analyzed is
indicated for each genotype. The number of replicate
experiments were: 5 WT, 5 trp-4, 4 unc-31, 4 unc13,
9 NLP-21, and 3 NLP-21+A. Values that are significantly
different from untreated wild-type controls are indicated
(***p < 0.001; **p < 0.01). Error bars indicate SEM.
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A Neuropeptide Mechanosensory Feedback Loop(Figure 2C), suggesting that expression in DVA is critical for NLP-
12’s function.
TRP-4 Is Required for Aldicarb-Induced Plasticity
DVA has been previously proposed to function as a stretch
receptor (Li et al., 2006). Bending of the worm’s body induces
calcium transients in DVA that are eliminated in mutants lacking
TRP-4, a mechanically gated ion channel (Kang et al., 2010;
Li et al., 2006). Prompted by these results, we tested the idea
that aldicarb-inducedmuscle contraction provides amechanical
stimulus that induces NLP-12 secretion. Consistent with this
idea, the aldicarb-induced decrease in NLP-12 puncta fluores-
cence was significantly reduced in trp-4 mutants (Figures 4A
and 4B; Figure S4B). This suggests that the ability of DVA to
sense mechanical stimuli is required to stimulate NLP-12
secretion.
If TRP-4 is required for aldicarb-induced NLP-12 secretion,
then we would expect that trp-4mutants would have behavioral
and electrophysiological defects similar to those observed in
nlp-12 mutants. As expected, trp-4 mutants were resistant to
aldicarb-induced paralysis (Figure 5F). In addition, like nlp-12
mutants, trp-4 mutants lacked the aldicarb-induced increase in
EPSC rate (Figures 5A and 5B) and in evoked synaptic charge
(Figures 5D and 5E), while baseline cholinergic transmission
was unaltered. Collectively, these results suggest that aldi-
carb-induced body muscle contractions induce NLP-12 secre-Neurontion, which subsequently potentiates ACh secre-
tion presynaptically.
NLP-12 Regulates Locomotion Behavior
Thus far, our results suggest that NLP-12 medi-
ates a mechanosensory feedback loop that
couples muscle contraction (induced by aldi-
carb treatment) to changes in presynaptic ACh
release. To determine if NLP-12 signaling has
an impact in the absence of aldicarb, we
analyzed the locomotion behavior of nlp-12
mutants. A prior study showed that bending of
the worm’s body during swimming behavior
induces calcium transients in DVA (Li et al.,
2006); consequently, we would expect that
NLP-12 secretion from DVA would also occurduring normal locomotion behavior. To assess changes in loco-
motion, we measured the velocity of worm locomotion. We
found that locomotion rate was significantly reduced in nlp-12
mutants and that this defect was rescued by an nlp-12 transgene
(Figures 6A and 6B). A similar locomotion defect was also
observed in ckr-2mutants, which was rescued by a ckr-2 trans-
gene expressed in cholinergic motor neurons (using the acr-2
promoter) (Figures 6A and 6B). These results suggest that
NLP-12 secretion modulates locomotion, consistent with the
idea that this mechanosensory feedback mechanism is engaged
during locomotion behavior.
To further investigate the connection between NLP-12 secre-
tion and locomotion rate, we analyzed NLP-12 secretion in
strains that have differing locomotion rates (Figure 6C). This anal-
ysis shows that increased locomotion rates (in npr-1 mutants)
are correlated with decreased NLP-12 puncta fluorescence,
whereas slow locomotion (inmec-3mutants) was accompanied
by increased NLP-12 puncta fluorescence. Thus, changes in
locomotion rate are accompanied by corresponding changes
in NLP-12 secretion.
DISCUSSION
We describe a mechanosensory feedback mechanism whereby
muscle contraction is coupled to changes in ACh release at
NMJs. This feedback mechanism consists of a stretch sensitive71, 92–102, July 14, 2011 ª2011 Elsevier Inc. 97
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Figure 5. The Mechanosensory Channel TRP-4 Is Required for Aldicarb-Induced Potentiation of Cholinergic Transmission
(A–E) Endogenous EPSCs (A–C) and stimulus-evoked EPSCs (D and E) were recorded from body wall muscle of adult worms of the indicated genotypes, with
(blue) and without (black) a 60 min aldicarb treatment. Representative traces of endogenous EPSCs (A), averaged stimulus-evoked responses (D), and summary
data (B, C, E) are shown.
(C) Cumulative probability distributions are shown for trp-4mutant endogenous EPSC amplitudes, with and without aldicarb treatment. No significant differences
were observed.
(F) Aldicarb-induced paralysis is compared for the indicated genotypes. The number of animals analyzed (B and E) or the number of replicate experiments (F) is
indicated for each genotype. Values that are significantly different from untreated wild-type controls are indicated (***p < 0.001; **p < 0.01). Error bars indicate
SEM. A common set of wild recordings (+ and – aldicarb) were utilized in Figures 1, 2, 3, and 5. All comparisons to this control data set were corrected for multiple
comparisons using the Tukey-Kramer test. All electrophysiological data are shown in Table S4.
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A Neuropeptide Mechanosensory Feedback Loopneuron (DVA), which secretes the neuropeptide NLP-12 in
response to muscle contraction. Activation of CKR-2, an NLP-
12 receptor, potentiates transmission at cholinergic NMJs. This
mechanosensory feedback is employed during spontaneous
locomotion behavior to determine locomotion rate. These exper-
iments define the synaptic basis for a simple proprioceptive
feedback circuit.
Activity-Dependent Plasticity at C. elegans Synapses
Aldicarb-induced paralysis has been extensively utilized as
a screening tool to identify C. elegans genes required for
synaptic transmission. Many genes identified as aldicarb resis-
tant mutants were subsequently shown to encode essential
components of the presynaptic release machinery (Sieburth
et al., 2005). Thus, it was somewhat surprising that neuropep-
tide-deficient mutants, which are all strongly aldicarb resistant,
have unaltered baseline synaptic physiology. Our results provide
an explanation for this puzzle. We show that brief aldicarb treat-
ments induce a form of synaptic potentiation, which is abolished
in the neuropeptide-deficient mutants. Several aspects of these
results are significant. These results represent the firstC. elegans
paradigm for activity-induced synaptic potentiation, and the first
study to document an electrophysiological effect of an endoge-
nous C. elegans neuropeptide. Our results also suggest that
additional genes involved in synaptic plasticity will be found98 Neuron 71, 92–102, July 14, 2011 ª2011 Elsevier Inc.among the genes identified in the prior screens for aldicarb-
resistant mutants.
NLP-12 Potentiates ACh Release at NMJs
Here we show that secretion of NLP-12 potentiates synaptic
transmission at cholinergic NMJs, and that it does so by
enhancing ACh release. Aldicarb treatment enhanced cholin-
ergic transmission, which was manifested by an increase both
in the rate of EPSCs and in the total synaptic charge evoked
by a depolarizing stimulus. Both effects of aldicarb were elimi-
nated by mutations inactivating NLP-12 and CKR-2 (an NLP-
12 receptor). NLP-12 is expressed by a single neuron DVA,
and aldicarb treatment induces NLP-12 secretion from these
neurons. Collectively, these results support the idea that aldicarb
treatment evokes NLP-12 secretion from DVA neurons, which
subsequently potentiates cholinergic transmission.
Several results suggest that the NLP-12-mediated potentia-
tion occurs by a presynaptic mechanism. First, the increase in
endogenous EPSCs frequency is characteristic of a presynaptic
change. Second, the amplitude and kinetics of endogenous
EPSCs were not altered by aldicarb treatment, implying that
muscle responses to individual synaptic quanta were unaltered.
Third, ACh-activated muscle currents were not increased by
aldicarb, suggesting that increased muscle sensitivity to ACh is
unlikely to explain the aldicarb-induced synaptic potentiation.
A B C
Figure 6. NLP-12 Regulates Locomotion Behavior
(A) Representative 30 s locomotion trajectories are shown (n = 20 animals for each genotype). The starting points for each trajectory were aligned for clarity.
(B) Locomotion rates are compared for the indicated genotypes. Pnlp-12 rescue refers to nlp-12mutants carrying a transgene containing a 2.1 kb genomic nlp-12
clone. Pacr-2 rescue refers to ckr-2mutants carrying a transgene driving CKR-2 expression in cholinergic motor neurons (using the acr-2 promoter). The number
of replicate experiments were: six WT, three nlp-12, three nlp-12 rescue, six ckr-2, and three ckr-2 rescue.
(C) Locomotion rates and NLP-12 puncta fluorescence intensities (both normalized to wild-type) are shown for npr-1 andmec-3mutants. The number of animals
analyzed is indicated for each genotype. The number of replicate experiments were: NLP-12 fluorescence in npr-1 (six WT, six npr-1); NLP-12 fluorescence in
mec-3 (four WT and fourmec-3); npr-1 locomotion (three WT and three npr-1);mec-3 locomotion (six WT and threemec-3). Values that are significantly different
from wild-type are indicated (***p < 0.001; **p < 0.01; *p < 0.05). Error bars indicate SEM.
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current amplitudes, consistent with decreasedmuscle sensitivity
to ACh. Identical decreases in ACh-activated currents were
observed in aldicarb treated nlp-12 and ckr-2mutants, suggest-
ing that this effect was not mediated by NLP-12. Fourth, the
ckr-2 mutant defects in aldicarb-induced potentiation, aldi-
carb-induced paralysis, and locomotion rate were all rescued
by transgenes expressing CKR-2 in the presynaptic cholinergic
neurons. Fifth, a ckr-2 transcriptional reporter was expressed
in cholinergic motor neurons, but was not expressed in body
muscles. Collectively, these results all support the idea that
increased ACh release accounts for NLP-12-mediated potentia-
tion of synaptic transmission.
Role of DVA as a Mechanosensory Neuron
A prior study showed that DVA neurons are stretch sensitive
(Li et al., 2006). Stretch sensitivity of DVA was documented by
observing calcium transients in DVA that are phasically activated
by body bends during swimming behavior (Li et al., 2006). These
swimming-induced DVA calcium transients were eliminated in
mutants lacking TRP-4, a mechanoreceptor (Kang et al., 2010;
Li et al., 2006).
Our results suggest that muscle contraction provides
a mechanical stimulus that induces DVA secretion of NLP-12.
NLP-12 is expressed only in DVA neurons, and it has a punctate
distribution in DVA axons, consistent with its packaging into
dense core vesicles (DCVs). Aldicarb treatment induces body
muscle contraction, which is accompanied by decreased
NLP-12 fluorescence in DVA axons. This aldicarb-induced
decrease of NLP-12 fluorescence is blocked by unc-31 CAPS
and unc-13 Munc13 mutations (which prevent DCV exocytosis)
and is diminished by trp-4mutations (which eliminate themecha-
nosensitivity of DVA). By contrast, aldicarb had little effect onsecretion of neuropeptides expressed by the DAmotor neurons,
implying that the effects of aldicarb on secretion are specific to
neuropeptides expressed by the DVA neurons. Collectively,
these results strongly support the idea that muscle contraction
provides a mechanical stimulus that evokes increased NLP-12
secretion from DVA. Electron microscopic analysis of the ventral
nerve cord also supports this idea. In the serial section recon-
struction of the nervous system, the DVA axon typically lies in
a dorsal position in the ventral nerve cord, adjacent to both
a muscle cell membrane, and to axons of cholinergic motor
neurons (typically VB neurons) (Figure S5) (White et al., 1986)
(www.wormimage.org). Thus, the DVA axon is well positioned
for its function as a sensor of body muscle contraction, and for
transducing this signal into altered cholinergic transmission.
Mechanosensory Control of Locomotion
In addition to its mechanosensory properties, DVA neurons were
proposed to regulate specific aspects of worm locomotion,
including the extent and speed of body bends during locomotion
(Li et al., 2006). Based on these observations, it was proposed
that DVA neurons act as stretch receptors, and perhaps function
in a manner analogous to proprioceptive neurons. However, the
synaptic basis for DVA-mediated regulation of locomotion had
not been described.
Our results provide a potential mechanism for DVA-mediated
regulation of locomotion rate. In particular, we propose that
body bends occurring during locomotion promote NLP-12
secretion from DVA neurons, thereby enhancing ACh release
at NMJs. Consistent with this idea, the locomotion rate of
nlp-12 and ckr-2 mutants was significantly reduced compared
to wild-type controls. This locomotion defect provides support
for the idea that NLP-12 secretion occurs during normal loco-
motion behavior, and that NLP-12 signaling is employed toNeuron 71, 92–102, July 14, 2011 ª2011 Elsevier Inc. 99
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utilized as an internal measure of recent locomotory activity. In
particular, during periods of elevated locomotion rates (e.g.,
during local search for food), increased body movements lead
to a net increase in NLP-12 secretion which would promote the
continued high rate of locomotion through enhanced ACh
release. A similar model was previously proposed for DVA func-
tion, based on the locomotion defects caused by laser killing
DVA neurons (Wicks and Rankin, 1995). In these experiments,
killing DVA neurons resulted in decreased forward and reverse
locomotion responses to a mechanical stimulus. Based on these
results, these authors proposed that DVA provides a gain control
that amplifies the locomotory response of animals to mechanical
stimuli (Wicks et al., 1996). Our results provide a potential
synaptic mechanism for these behavioral effects.
EXPERIMENTAL PROCEDURES
Strains
Strain maintenance and genetic manipulation were performed as described
(Brenner, 1974). Animals were cultivated at 20C on agar nematode growth
media seeded with OP50 bacteria.
KP5994 nlp-12(ok335)I
LSC32 ckr-2(tm3082)III
TQ296 trp-4(sy695)I
CB1338 mec-3(e1338)IV
KP6048 npr-1(ky13)X
KP6199 nlp-12(ok335)I;ckr-2(tm3082)III
KP6405 nuIs441 (Pnlp-12::nlp-12::YFP)
KP6377 unc-13(s69)I; nuIs441
KP6373 unc-31(e928)IV; nuIs441
KP6376 trp-4(sy695)I; nuIs441
KP6406 trp-4(sy695)I; nuIs441 1x out-crossed
KP6545 mec-3(e1338)IV; nuIs441
KP6546 npr-1(ky13)X; nuIs441
BC168 unc-13(s69)I
CB928 unc-31(e928)IV
KP3945 nuIs181 (Punc-129::nlp-21::YFP)
KP5966 egl-3(nr2090)V
KP6202 nlp-12(ok335)I; egl-3(nr2090)VExtrachromosomal Arrays
KP6450 nuEx1476 (Punc-25::ckr-2)
KP6449 nuEx1475 (Punc-17::ckr-2)
KP6575 nuEx1500 (Pacr-2::ckr-2::YFP)
KP6319 nuEx1463 (Pnlp-12::nlp-12::YFP)
KP6404 nuEx1474 (Pnlp-12::nlp-21::YFP)
KP6551 nuEx1487 (Punc-129::nlp-12::YFP)
KP6552 nuEx1488 (Punc-129::nlp-12::YFP)
KP6577 nuIs392, nuEx1501 (Punc-17::mCherry + Pckr-2::NLS::GFP)
KP6578 nuIs428, nuEx1501 (Punc-25::mCherry + Pckr-2::NLS::GFP)Constructs and Transgenes
Pnlp-12::nlp-12::YFP
A 2.1 kb nlp-12 genomic region, 383 bp upstream of the start codon and
1374 bp downstream of the stop codon, was amplified by PCR. The stop
codon of nlp-12 was replaced by an MluI site by overlap extension PCR,
and YFP (venus) was inserted in the MluI site, and its orientation confirmed
by sequencing.
Punc-129::nlp-12::YFP
A cDNA corresponding to nlp-12 was amplified by PCR and inserted into
KP#1284 using gateway cloning (Sieburth et al., 2005).100 Neuron 71, 92–102, July 14, 2011 ª2011 Elsevier Inc.ckr-2 Rescue
A CKR-2a cDNA clone (Janssen et al., 2008) was kindly provided by Liliane
Schoofs. The cDNAwas ligated into expression vectors (pPD49.26) containing
the unc-17 promoter (for cholinergic rescue), the acr-2 promoter (for cholin-
ergic motor neuron rescue), or the unc-25 promoter (for GABAergic rescue).
ckr-2 Transcriptional Reporter
An 8.5 kb fragment of ckr-2 genomic region, from 3008 bp upstream of the
start codon to 20 bp into the second exon, was fused to a GFP containing
four nuclear localization signals.
Transgenes and Germline Transformation
Transgenic strains were isolated by microinjection of various plasmids using
either Pmyo-2::NLS-GFP (KP#1106) or Pmyo-2::NLS-mCherry (KP#1480) as
coinjection markers. Integrated transgenes were obtained by UV irradiation
of strains carrying extrachromosomal arrays. All integrated transgenes were
outcrossed at least six times.
Locomotion and Behavior Assays
For aldicarb paralysis, between 18 and 25 young adult wormswere transferred
to plates containing 1.5 mM aldicarb and assayed for paralysis as described
previously (Nurrish et al., 1999). Worm tracking and analysis were preformed
similar to previous studies (Dittman and Kaplan, 2008) with minor modifica-
tions. Briefly, worms were reared at 20C and moved to room temperature
30 min before imaging. Young adult animals were picked to agar plates with
no bacterial lawn (30 worms per plate) and were transferred to second plate
lacking bacteria after 5–10 min. Worm movement recordings were started
40–45 min after the worms were removed from food. Thirty second digital
videos of individual animals were captured at 53magnification and 4 Hz frame
rate on a Zeiss Discovery Stereomicroscope using Axiovision software. The
center of mass was recorded for each animal on each video frame using the
object tracking in the Axiovision software. The trajectories were then analyzed
using custom software written in Igor Pro 5.0 (Wavemetrics). For all compari-
sons to untreated wild-type controls, statistical significance was determined
using the Tukey-Kramer test to control for multiple comparisons. For all pair-
wise comparisons of mutant and transgenic rescue strains, statistical signifi-
cance was determined using a two-tailed Student’s t test.
Fluorescence Imaging
All quantitative imaging was done using an Olympus PlanAPO 1003 1.4 NA
objective and a CoolSNAP CCD camera (Hamamatsu). Worms were immobi-
lized with 30 mg/ml BDM (Sigma). Image stacks were captured and maximum
intensity projections were obtained using Metamorph 7.1 software (Molecular
Devices). YFP fluorescence was normalized to the absolute mean fluores-
cence of 0.5 mm FluoSphere beads (Molecular Probes). For ventral or dorsal
cord imaging, young adult worms, in which the ventral or dorsal cords were
oriented toward the objective, were imaged in the region just posterior to the
vulva. Imaging was done prior to aldicarb treatment and after 60 min of
1.5 mM aldicarb treatment. Line scans of ventral and dorsal cord fluorescence
were analyzed in Igor Pro (WaveMetrics) using custom-written software to
identify average peak fluorescence values for all puncta in the imaged region
(peak punctal intensity) (Dittman and Kaplan, 2006). For coelomocyte imaging,
the posterior coelomocyte was imaged in larval stage 4 (L4) and early adult
worms (Sieburth et al., 2007). For all comparisons to untreated wild-type
controls, statistical significance was determined using the Tukey-Kramer
test to control for multiple comparisons. For all comparisons of control and al-
dicarb treated animals of the same genotype, statistical significance was
determined using a two-tailed Student’s t test.
Electrophysiology
Electrophysiology was done on dissected C. elegans as previously described
(McEwen et al., 2006). Worms were superfused in an extracellular solution
containing 127 mM NaCl, 5 mM KCl, 26 mM NaHCO3, 1.25 mM NaH2PO4,
20 mM glucose, 1 mM CaCl2, and 4 mM MgCl2, bubbled with 5% CO2,
95% O2 at 20
C. Whole cell recordings were carried out at –60 mV using an
internal solution containing 105 mM CH3O3SCs, 10 mM CsCl, 15 mM CsF,
4 mMMgCl2, 5mMEGTA, 0.25 mMCaCl2, 10 mMHEPES, and 4mMNa2ATP,
adjusted to pH 7.2 using CsOH. Under these conditions, we only observed
Neuron
A Neuropeptide Mechanosensory Feedback Loopendogenous acetylcholine EPSCs. For endogenous GABA IPSC recordings
the holding potential was 0 mV. All recording conditions were as described
(McEwen et al., 2006). Stimulus-evoked EPSCs were stimulated by placing
a borosilicate pipette (5–10 mm) near the ventral nerve cord (one muscle
distance from the recording pipette) and applying a 0.4ms, 30 mA square pulse
using a stimulus current generator (WPI). For aldicarb exposure, a single adult
worm was transferred to a plate containing 1 mM aldicarb for 60 min prior to
the dissection, with one exception, ckr-2 ACh rescue animals were treated
for 30 min. For all comparisons to untreated wild-type controls, statistical
significance was determined using the Tukey-Kramer test to control for
multiple comparisons. For all comparisons of control and aldicarb-treated
animals of the same genotype, statistical significance was determined using
a two-tailed Student’s t test.SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and four tables and can be
found with this article online at doi:10.1016/j.neuron.2011.04.021.
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